ADVFN Logo
Boards:
    Quotes:
      Boards
      News
      Market Data
      Markets
      Discover
      AI Subscribe Login/Register Profile Icon
      S&P 500
      5,738.52
      -1.78%
      US Tech 100
      19,620.80
      -2.29%
      Dow Jones
      42,579.08
      -0.99%
      Brent Oil
      69.34
      0.00%
      Bitcoin
      87,759.95
      -2.40%
      Registration Strip Icon for discussion Register to chat with like-minded investors on our interactive forums.
      Get Started
      1. Home
      2. Investing
      3. Stocks
      4. USA
      5. NASDAQ
      6. Anavex Life Sciences Corporation (AVXL)

      7. Anavex Life Sciences Corporation (AVXL) News

      Anavex Life Sciences Corporation

      Anavex Life Sciences Corporation (AVXL)

      NASDAQ
      8.59
      -0.14
      (-1.60%)
      Closed March 06 4:00PM
      Delayed by 15 minutes
      8.59
      0.02
      (0.23%)
      After Hours: 7:55PM
      Delayed by 15 minutes

      Your Hub for Real-Time streaming quotes, Ideas and Live Discussions

      Premium

      AVXL News

      Official News Only

      Form 10-Q - Quarterly report [Sections 13 or 15(d)]
      Edgar (US Regulatory)
      February 12 2025
      AVXL (-1.60%)

      Form 4 - Statement of changes in beneficial ownership of securities
      Edgar (US Regulatory)
      January 17 2025
      AVXL (-1.60%)

      Form 4 - Statement of changes in beneficial ownership of securities
      Edgar (US Regulatory)
      December 23 2024
      AVXL (-1.60%)

      Form 10-K - Annual report [Section 13 and 15(d), not S-K Item 405]
      Edgar (US Regulatory)
      December 23 2024
      AVXL (-1.60%)

      AVXL Discussion

      View Posts
      rx7171 rx7171 4 minutes ago
      Isn’t this what the company did when they extended the AD Phase 2a/b into the Phase 2b/3 trial currently used as the basis for the EMA MAA?
      👍️0
      Hoskuld Hoskuld 2 hours ago
      That is true but they won't do that in this case. There is no need. They need the results to show the value and make themselves more of a takeover candidate a la Karuna. The 2 P3 trials that would follow would go quickly and be pro forma if the P2b results are excellent.
      👍️ 1
      rx7171 rx7171 2 hours ago
      An important comment was made concerning animal model preclinical data indicated that after 3-71 treatment was stopped the benefit did not return to the previous disease state.
      That if verified in our trial would be amazing and truly unexpected since it sounds like a cure not just a treatment.

      However from a business perspective more money is made with a continuing application of a medication compared to a single curative application.
      👍️0
      dia76ca dia76ca 2 hours ago
      Cobenfy clearly has some important benefits but also some very unpleasant side effects. My understanding is that Anavex 3-71 has far fewer side effects. And if its long term use pattern is similar to blarcamesine its efficacy and safety continues for many years!
      https://www.yalemedicine.org/news/3-things-to-know-about-cobenfy-the-new-schizophrenia-drug
      👍️ 2
      dia76ca dia76ca 3 hours ago
      We don't know what has been discussed with the FDA. However if the expanded 2b showed very certain efficacy and amazingly pristine safety data...could it receive accelerated approval ? Current treatments all have significant problems. Such things have occurred!
      👍️ 1
      skitahoe skitahoe 3 hours ago
      It may be possible to expand a Phase 2 into Phase 3, or just expand it and actually go for approval from the larger Phase 2 as long as the trial is being done with Pivotal quality material.

      Gary
      👍️ 1
      rx7171 rx7171 4 hours ago
      Actually the 3-71 is a Phase 2a/b trial.
      It is now in the 2b point with a larger treatment cohort than was originally planned
      Hopefully large enough to get a strong positive p value to justify a large pivotal Phase 3.
      👍️0
      BIOChecker4 BIOChecker4 4 hours ago
      What happened? Did the FUDsters, bashers and short sellers paint the tape near the close?
      👎️ 1 👺 1 🖌️ 1 🤪 1
      kspar1 kspar1 5 hours ago
      OK, went back to listen to it again and, regarding the EMA submission, they add... "and it was accepted for review late last year."
      So, that would mean late December, right? Given that the parallel 3-71/schizophrenia trial was public knowledge at the time, that, to me, just reinforces the likelihood that they decided to keep the focus of their video about ALZ. I think that's a smart move when the goal is to introduce what can be an overwhelming wave of potential AVXL product candidates.
      👍️ 2
      BDR10 BDR10 5 hours ago
      Not really much to say it's pretty much low volume and pennies either way just about every day
      💤 1
      Steady_T Steady_T 5 hours ago
      The overview explicitly talked about 3-71 having only pre clinical trials. Given that the discussion seemed to be pretty well researched that suggests to me that it was made before the schizophrenia P1 was announced.
      👍️ 1
      kspar1 kspar1 5 hours ago
      re: stockexplorer's Anavex overview, hope everybody is forwarding the link.
      A very upbeat, encouraging and clear perspective on the MOAs of Blarcamesine and 3-71.
      Definitely perfect for first-pass education of the masses (of potential investors).

      It shows "22 hours" was how long ago video was installed in Youtube. Anybody know when the video was actually created? The absence of any reference to Schizophrenia was odd, but perhaps they decided to focus solely on Alzheimers and avoid confusing their audience with the myriad proposed targets for both drugs.

      In 1995, I ran a company in Santa Cruz, CA that developed a new server for building high-end Web apps, a big deal then. Until they came up with better strategies, our sales people hated selling it because talking to perspective clients, the last thing they wanted to say was "anything!" A lesson I carried with me the rest of my now-completed career.
      👍️ 2
      Steady_T Steady_T 6 hours ago
      Very well done discussion of Anavex drug pipeline and why it has promise.

      It is old enough that it doesn't mention that 3-71 is now in P2 trials for schizophrenia. That was the only shortcoming.

      Thanks for bringing that to the board.
      👍️ 2
      D-Mike D-Mike 7 hours ago
      Great question! I’m curious to see what kind of replies this generates. I’m hopeful that increased % holding by tutes will put an end to the insane manipulation but I may be nuts.
      👍️ 2
      mike_dotcom mike_dotcom 7 hours ago
      Can't fight this schitty market.
      👍️0
      georgejjl georgejjl 8 hours ago
      AVXL



      Good luck and GOD bless,
      👍️ 8 💥 1
      georgejjl georgejjl 8 hours ago
      Expect AVXL to close GREEN today in anticipation of good news next week regarding AVXL stock!!!

      Good luck and GOD bless,
      🤓 1 🥸 1
      baltimorebullet baltimorebullet 8 hours ago
      Thank you (and ignatiusrielly35).
      This one seems perfect for me if you click on the 5 day and then the 1 day.

      https://www.nasdaq.com/market-activity/stocks/avxl/advanced-charting
      👍️ 1
      LakeshoreLeo1953 LakeshoreLeo1953 10 hours ago
      And once you find the number(s) you then must decipher what they mean.
      is it an individual(s) trade?
      Is it covering a short be it long or short term?
      Is it adding or beginning acquisition?

      MOC is many things and almost exclusively a "pros" tool.
      👎️ 1 👺 2
      ignatiusrielly35 ignatiusrielly35 10 hours ago
      My online brokers quote shows the last trade of the regular session by volume and price. You can also see a list of ALL individual trades at the NASDAQ website, including the time stamp. 
      👍️ 3
      k9uwa k9uwa 10 hours ago
      MOC totals. Look to the right on any IHub page. Just below the note that says Delayed by 15 minutes are two charts. Click on the 1D and you will see the price in the upper portion and below it the volume chart. You can watch the price as well as the volume through the day. Then at 16:00 + 15 minutes you will see the spike for the MOC order total. Or yes on my brokers site if I click on a stock I own to put in a trade up comes the Bid / Ask / Volume today total. So if I click on AVXL stock at 15:50 10 seconds prior to normal close for the day I see Bid Ask and Volume total. Then reclick on it at 16:00: 15seconds after the close then I get the volume of Total for the day.. subtract the 15:59 volume and you have the MOC total. Yesterdays MOC total was something around 125,000 shares.

      John k9uwa
      👍️ 1
      tschussmann1 tschussmann1 10 hours ago
      Question for the board: is there a point where the level of institutional ownership becomes a driving force for stock price? I speculate that institutions are continuing to buy and that we are probably nearing 50 percent at this point in time.
      👍️ 6
      georgejjl georgejjl 10 hours ago
      Both Anavex’s blarcamesine and/or Anavex3-71 will prove to be an effective treatment and prevention for ALS (Lou Gehrig’s) disease,

      “… The sigma-1 receptor (S1R) is a protein in the endoplasmic reticulum (ER) that is linked to amyotrophic lateral sclerosis (ALS). The S1R is a potential therapeutic target for ALS and other neurodegenerative disorders….”

      https://link.springer.com/article/10.1007/s43440-021-00310-7

      Good luck and GOD bless,
      👍️ 5 💥 1
      Hoskuld Hoskuld 11 hours ago
      Genentech already had a relationship with Roche - they were successful with herceptin, avastin, and other products. My company actually did a fair amount of work with them. Genentech was a fully vertically integrated company, too. All in all, I agree that $70b would be an acceptable price.
      👋 2 👍️ 4
      Citrati Citrati 11 hours ago
      The simple answer is that despite the market volatility and the sector drop of XBI, AVXL is holding up well and is in building mode in anticipation of some good news.
      That said, in order to take full advantage of that good news price getting above that top long blue horizontal line and making it support is where we want the base for the spring upward if/when that news comes. If it is huge good news then it doesn't matter nearly as much for the initial surge, but may come into play as a level for price to retest if the buying surge is short lived.
      If price today and tomorrow close above and cause the 4,8and 13 ema's to stack fastest to slowest (4 on top and leading the group upward) and increase separation, that raises the odds for price to attack the top horizontal blue line and make the entire zone from bottom line to top support. It also establishes the green 100period moving average as support.
      If/when price can make the brown 50period moving average support then price would be set up to make maximum usage of major news.
      Also the sharper the upward angle of ema's and ma's the more support they give to price retrace and forming support levels.

      If you look at the the bands, price is in the upper half of the bands and nearing the upper band so it can potentially push price upward. What is forming is increasing the odds that a breakout upward is likely to occur. The upper blue horizontal is at 9.25. Right now that upper bb is at 9.73. If/when price reaches there, if there is enough buying strength that band will turn up and price can eventually attack and turn up the purple kchannel band and that is when all the big numbers that get thrown out can finally come into focus again. There is still some resistance from 10.60-11.40 as denoted by that next longest VbP bar zone and then above that one needs to look back longer than 6 months to find resistance price lines and zones.

      That is a lot, but not all that goes into the picture if one adds the use of indicators and overbought/oversold price movement. It is however sufficient to get a decent picture of the future. If price were in a down trend the same information is used in an opposite set up of the lines, moving averages and bands.

      Hope that was informative and not just brain overload. Green Trades.

      Obviously, this did not cover trading around a core buying and selling. If an investor is simply a hold or fold type then none of that really matters because they only look at fundamentals instead of combining it with technical analysis.
      👍️ 7 🙏 1 🫡 1
      dia76ca dia76ca 11 hours ago
      In 2009 Roche bought Genentech for $47 billion. In 2025 dollars they paid $70 billion. The big attraction for Roche was Avastin to treat cancer.
      What will Anavex be worth when both blarcamesine and Anavex 3-71 are approved for dozens of CNS disease indications?
      Will Anavex be worth $70 billion? Or will it be worth more than $70 billion?
      🏆️ 1 👍️ 13 👏 2 💥 3 😃 1 🧠 1
      oldmystic oldmystic 11 hours ago
      https://www.tizianalifesciences.com/tiziana-life-sciences-files-investigational-new-drug-application-with-fda-for-als-phase-2-clinical-trial/
      👍️0
      Hoskuld Hoskuld 13 hours ago
      Citrati, how do you read that? What is your prediction based on all those trends and bands?
      👍️0
      Hoskuld Hoskuld 13 hours ago
      Could happen.
      👍️0
      chrismiss_everyday chrismiss_everyday 16 hours ago
      worth noting…

      https://www.marketscreener.com/quote/stock/GENENTECH-INC-12326/
      👍️ 4
      Citrati Citrati 22 hours ago
      Very nice close and continued building. Hoping for more follow through and making the hundred period support to close the week.

      https://investorshub.advfn.com/uimage/uploads/2025/3/5/ddgkeScreen_Shot_2025-03-05_at_9.39.25_PM.png
      👍️ 4
      RedShoulder RedShoulder 1 day ago
      "Y Intercept Hong Kong Ltd Makes New $243,000 Investment in Anavex Life Sciences Corp. (NASDAQ:AVXL)"

      Posted by Defense World Staff on Mar 5th, 2025

      A number of other large investors also recently modified their holdings of AVXL. Geode Capital Management LLC raised its stake in Anavex Life Sciences by 2.8% during the third quarter. Geode Capital Management LLC now owns 1,883,199 shares of the biotechnology company’s stock worth $10,699,000 after acquiring an additional 51,946 shares during the period. Nwam LLC bought a new position in shares of Anavex Life Sciences during the third quarter valued at approximately $5,172,000. Charles Schwab Investment Management Inc. raised its position in shares of Anavex Life Sciences by 2.3% during the 3rd quarter. Charles Schwab Investment Management Inc. now owns 665,976 shares of the biotechnology company’s stock worth $3,783,000 after purchasing an additional 14,892 shares during the period. Barclays PLC lifted its holdings in shares of Anavex Life Sciences by 70.4% in the 3rd quarter. Barclays PLC now owns 155,179 shares of the biotechnology company’s stock worth $882,000 after purchasing an additional 64,101 shares during the last quarter. Finally, Rhumbline Advisers boosted its position in Anavex Life Sciences by 2.9% during the 4th quarter. Rhumbline Advisers now owns 123,699 shares of the biotechnology company’s stock valued at $1,329,000 after purchasing an additional 3,498 shares during the period.

      https://www.defenseworld.net/2025/03/05/y-intercept-hong-kong-ltd-makes-new-243000-investment-in-anavex-life-sciences-corp-nasdaqavxl.html

      Thanks to bjc60 on ST.
      👍️ 13
      Hoskuld Hoskuld 1 day ago
      Yes, Boi, I agree that the 3 major issues probably won't prevent Anavex from winning the day. But, they are real and will be considered at length behind closed doors - and may generate some questions from the EMA, too, along the way.
      👎️ 3 👺 3
      Hoskuld Hoskuld 1 day ago
      The poster I responded to asked the question and my answer was accurate, I think. I actually think that there is not enough data to make the discussion about those 3 points moot, but enough data to make the EMA decide in Anavex's favor.
      👍️ 3
      williamssc williamssc 1 day ago
      16:00:00 8.73 119,269 Buy--
      Another big buy at the close
      👍️ 4
      rayovac812 rayovac812 1 day ago
      https://ih.advfn.com/stock-market/NASDAQ/anavex-life-sciences-AVXL/trades

      ....or anywhere you can get time and sales at 16:00(4PM)
      👍️0
      ohsaycanyousee82 ohsaycanyousee82 1 day ago
      Dr. Bhattacharya in his confirmation hearing says he wants to shift NIH focus to chronic diseases like obesity, Alzheimer’s and cancer. Wants free speech and open scientific dialogue.

      Gee, I wonder how that might benefit Anavex Life Sciences?
      👍️ 18 👎️ 1 👺 1 💯 2
      dia76ca dia76ca 1 day ago
      There are bear arguments.
      But there are not many.
      And the few that there are, are very weak.
      If the Mabs, with all their problems, were approved, blarcamesine should be a slam dunk!
      👍️ 14 😀 1 😃 1
      kspar1 kspar1 1 day ago
      My guess is EMA knew the trial sizes when deciding to invite Anavex to apply.
      👍️ 10
      Hoskuld Hoskuld 1 day ago
      Yes, as I wrote, I think these issues can be overcome. But that is the list.
      👍️ 2 👎️ 1 👺 1
      boi568 boi568 1 day ago
      If blarcamesine lives up to its promise, AD patients taking the drug will have their lives extended by a number of years beyond present day life expectancy.
      👍️ 11 😀 1 🧠 1
      plexrec plexrec 1 day ago
      "--Closes the day with real style."--agree--great week so far--Cowen C.C. got this moving--we traded at $7.95 this past Monday--folks catching on--huge winner here !!!!
      👍️ 6
      boi568 boi568 1 day ago
      I think your list of "why not" is probably better stated as, "because there has been only one small trial for a huge indication there is not enough safety data, and, besides, there is also not enough long term data."

      The central counterargument is that all of this was known at the time the EMA gave Anavex the green light to submit an MAA -- and to apply without conditions. We get some indirect support for sufficient trial size by our AD 2b/3 from an FDA drug rejection to a competitor on the basis that there were fewer than only 100 treated patients, implying a dosed arm can be sufficient at a much smaller size than the Anavex trial. And I suspect that the nature of our MOA -- a restoration of immune function -- is not, unlike the MAB's inflammatory strategy, raising health issues. We have not seen a safety concern arise in the recent S1R literature.

      And while we rather recently learned the top line of the OLE, showing a long-term effect, that information may have been known in the pre submission period. (In fact, it's even better if it hadn't been known at the time of the CHMP go-ahead.) MAB competitors have not provided nearly as long an efficacy period, and I don't recall a regulatory agency criticizing a submission on that basis.

      Finally, we know that the regulatory agencies are motivated to address the unmet health needs presented by the lack of an effective AD medication.
      🏅 3 👍️ 28
      Steady_T Steady_T 1 day ago
      I suggest that if those items were an issue the applications would have been rejected already.
      Those are issues that get looked at early on in the evaluation.
      👍️ 10 😀 1
      Bourbon_on_my_cornflakes Bourbon_on_my_cornflakes 1 day ago
      $uper finish now
      Beautiful pennant today
      Accumulation.

      Pennant soaring upward.
      Indications tutes' feeding.
      Accumulation

      What is the sound of
      A big whale gorging on shares?
      Accumulation.

      120K trade
      Closes the day with real style.
      Accumulation.
      👍️ 4 😁 1
      Bourbon_on_my_cornflakes Bourbon_on_my_cornflakes 1 day ago
      not problems

      2. not enough safety data (c'mon, there hasn't been anyone reporting significant side effects, no brain bleeding. no one has died)
      3. not enough long term data (some people have been on this for 4-5 years now, that is pretty long term, longer than most with alz will live)
      👍️ 7 😁 3
      Bourbon_on_my_cornflakes Bourbon_on_my_cornflakes 1 day ago
      not sure about that: "I don't favor a future partner taking an equity stake in Anavex. I think that deal favors the partner rather than us. It's a variant of an early buyout"

      It works if the standstill agreement is long enough and AVXL and partner work to maximize market for 273 and 371

      Genentech is the template.
      👍️ 4 💯 1 🤑 1
      Bourbon_on_my_cornflakes Bourbon_on_my_cornflakes 1 day ago
      DISAGREE: The 18-24 mo standstill simply allows for value to build during initial launch and for excitement to build for buyout. FWIW, I want Anavex purchased for a premium by a company that can maximize the potential of its pipeline.

      Dont want to sell in 2 years, that is a $20B deal max.

      Partner can help us just as well without buying us, especially since $1 billion cash upfront will fund numerous trials without dilution for years.

      Let business grow, get big and profitable. Partner does well, we do well. 273 and 371 get approved for numerous indications. Share price rises to $1249. Then a buyout at $1,500-$2,000 a share. That is why you need a 10 years standstill agreement.
      👍️ 16 👏 1 💯 1 🤑 1
      georgejjl georgejjl 1 day ago
      AVXL closed up $0.32 with a buying volume 775,533

      https://www.nasdaq.com/market-activity/stocks/avxl/after-hours-trades?page=2&rows_per_page=20

      Good luck and GOD bless,
      👍️0
      Hoskuld Hoskuld 1 day ago
      Why wouldn't EMA approve blarcamesine?

      The reasons have been put out here quite a few times:

      1. only one small trial for a huge indication
      2. not enough safety data
      3. not enough long term data

      Some people might also cite ADL endpoint not being stat sig, but I don't think that is a legit objection

      I think there is a good chance the EMA will look past the above -and the PDD and the Rett trials in aggregate may answer #2.
      👍️ 1 👎️ 3 👺 1

      Your Recent History

      NASDAQ
      AVXL
      Anavex Life Sciences
      Delayed Upgrade Clock

      Go Ad-Free

      Subscribe to Ad free and enjoy an ad-free experience

      No Ads

      Try Now

      Keep the Ads